November 12, 2012 at 10:38 AM EST
Clovis Oncology (CLVS) falls on negative drug test outcome
Normal 0 false false false MicrosoftInternetExplorer4 Clovis Oncology (NASDAQ: CLVS) shares fell 38.3% to $11.27. Clovis Oncology reported negative outcome of CO-101 in pivotal LEAP pancreatic cancer study. Share volume was 966,000, dwarfing a daily average of less than 71,000. /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:"Times New Roman"; mso-ansi-language:#0400; mso-fareast-language:#0400; mso-bidi-language:#0400;}
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here